Medi-Span Substitution Groups is a supplemental drug data content set offered by Wolters Kluwer's Medi-Span, a leading provider of embedded drug data solutions in the healthcare industry. It is designed to help healthcare organizations, such as payers, PBMs, and EMR vendors, manage the complexities of the evolving biosimilar landscape. The file is a supplement to core Medi-Span drug information databases, like MED-File v2.
Key Capabilities:
- Biosimilar Tracking: Provides up-to-date information concerning drugs classified as biosimilars.
- Interchangeability Ratings: Supplies data on whether biosimilar drugs are rated as 'Interchangeable' or 'Biosimilar' to guide substitution decisions.
- Grouping for Reporting: Allows users to group biosimilar drugs for reporting purposes.
- Relationship Mapping: Shows the relationships between originator and reference drugs.
- Integration: The data is designed to be integrated into existing healthcare systems (EMRs, pharmacy systems, claims processing) to support real-time decision-making.
Target Users and Use Cases:
The product is primarily a data backbone for other digital healthcare systems. Target users include:
- Payers and Pharmacy Benefits Managers (PBMs): For formulary management and claims processing.
- Healthcare Technology Companies/EMR Vendors: To embed accurate substitution data into clinical decision support systems.
- Retail Pharmacies and Hospitals: To support generic and therapeutic substitution at the point of dispensing or prescribing.
Medi-Span data is available via flat files, API, and Web Services, enabling flexible deployment and integration into various digital healthcare systems.